Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
This review highlights the need for standardized methodologies in clinical trials for HSDD to improve the quality of evidence and facilitate better clinical interpretation.
Where it sits
this study against the rest of the pt-141 (bremelanotide) corpusSummary and findings
This systematic review evaluated completed interventional clinical trials for pharmacological therapies targeting hypoactive sexual desire disorder (HSDD) in adult women. It primarily focused on studies involving bremelanotide and flibanserin, assessing their efficacy and safety outcomes. The review highlighted variability in trial design and outcome reporting.
Abstract
<h4>Background</h4>Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting adult women and is associated with significant impairments in quality of life and interpersonal relationships. Despite increasing recognition of female sexual health as a clinical priority, pharmacological treatment options for HSDD remain limited, and evidence from individual clinical trials remains heterogeneous. Therefore, a systematic evaluation of registered clinical trials is essential to better understand therapeutic development, efficacy endpoints, and safety profiles of emerging treatments.<h4>Methods</h4>This systematic review was conducted in accordance with PRISMA 2020 guidelines using a structured search of ClinicalTrials.gov. Completed interventional clinical trials evaluating pharmacological therapies for HSDD in adult women were identified using predefined eligibility criteria. Data were extracted on study design, participant characteristics, investigational agents, efficacy outcomes related to sexual desire and distress, and reported safety outcomes. Findings were synthesized descriptively without pooled quantitative analysis.<h4>Results</h4>A total of nine completed pharmacological clinical trials met the inclusion criteria. Most were Phase II and Phase III randomized, double-blind, placebo-controlled studies, primarily enrolling premenopausal women with acquired, generalized HSDD. Investigational therapies predominantly targeted central nervous system pathways, with flibanserin and bremelanotide representing the most extensively studied agents. Efficacy outcomes commonly included validated patient-reported measures such as the Female Sexual Function Index desire domain and the Female Sexual Distress Scale; however, endpoint designation and reporting completeness varied across trials. Safety data were inconsistently reported, with adverse events reflecting the pharmacological mechanisms of the agents studied.<h4>Conclusion</h4>The findings highlight both progress and persistent gaps in the pharmacological treatment landscape for HSDD. Variability in trial design, outcome measures, and reporting practices limits cross-trial comparison and clinical interpretation. Further research with standardized methodologies and comprehensive reporting is needed to strengthen the evidence base.
Background
Hypoactive sexual desire disorder (HSDD) in women is a condition characterized by a lack of sexual desire that can affect quality of life. Prior studies have explored various pharmacological interventions, including PT-141 (Bremelanotide), but comprehensive evaluations of their efficacy and safety are limited. This systematic review aims to synthesize available clinical trial data to inform practitioners about emerging therapies for HSDD.
Methods
The review included completed studies registered on ClinicalTrials.gov, focusing on pharmacological treatments for HSDD in women. Specific details regarding the study design, population, sample size, doses, and duration of treatment were not reported in the abstract. Primary and secondary outcome measures were also not specified.
Results
Not reported in abstract.
Interpretation
Without specific results reported, it is challenging to compare the findings of this review with existing literature on PT-141 or other therapies. The lack of detailed outcomes limits the ability to assess the clinical significance of any reported effects. Potential confounds include the absence of detailed methodology and outcome measures, which may affect the reliability of the conclusions drawn.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- No specific data on PT-141 or other therapies.
- Lack of detailed methodology and outcomes.
- No sample size or demographic information provided.